



Reference:

1. Cholib Hong Kong Full Prescribing information
2. Ginsberg et al. N Engl J Med 2010 ; 362(17) : 1563-74

**NAME OF THE MEDICINAL PRODUCT, CHOLIB TABLETS 145MG/20MG; QUALITATIVE AND QUANTITATIVE COMPOSITION:** One film-coated tablet contains 145 mg of fenofibrate and 20 mg of simvastatin. **Therapeutic indications:** Cholib is indicated as adjunctive therapy to diet and exercise in high cardiovascular risk adult patients with mixed dyslipidaemia to reduce triglycerides and increase HDL-C levels when LDL-C levels are adequately controlled with the corresponding dose of simvastatin monotherapy. **Poology and method of administration:** Secondary causes of hyperlipidaemia, such as uncontrolled type 2 diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemia, obstructive liver disease, pharmacological treatment (like oral oestrogens), alcoholism should be adequately treated, before Cholib therapy is considered and patients should be placed on a standard cholesterol and triglycerides-lowering diet which should be continued during treatment. **Contraindications:** Hypersensitivity to the active substances, peanut, soya or to any of the; Known photoallergy or phototoxic reaction during treatment with fibrates or ketoprofen; Active liver disease or unexplained persistent elevations of serum transaminases; Known gallbladder disease; Chronic or acute pancreatitis with the exception of acute pancreatitis due to severe hypertriglyceridaemia; Moderate to severe renal insufficiency (estimated glomerular filtration rate < 60 mL/min/1.73 m<sup>2</sup>); Concomitant administration of fibrates, statins, danazol, cyclosporin or potent cytochrome P450 (CYP) 3A4 inhibitors; Concomitant administration of glimepiride, pioglitazone, elbasvir or grazoprevir; Paediatric population (age below 18 years); Pregnancy and breast-feeding; Personal history of myopathy and/or rhabdomyolysis with statins and/ or fibrates or confirmed creatine phosphokinase elevation above 5 times the upper limit of normal (ULN) under previous statin treatment; Concomitant administration of amiodarone, verapamil, amlodipine or diltiazem; strong CYP3A4 inhibitors (e.g. itraconazole, ketoconazole, posaconazole, voriconazole, HIV protease inhibitors, boceprevir, telaprevir, erythromycin, clarithromycin, telithromycin and nefazodone), gemfibrozil, ciclosporin and danazol. **Special warnings and precautions for use:** Simvastatin 80 mg should be used only in patients who have been taking this dose for 12 months or more without evidence of muscle toxicity; Simvastatin 80mg should not be started in new patients, including patients already taking lower doses of the drug; It is recommended that liver function tests should be performed before the initiation of Cholib, and thereafter when clinically indicated; Interaction with other medicinal products and other forms of interaction: Do not exceed 10 mg simvastatin daily with verapamil, diltiazem and other fibrates (except fenofibrate); Do not exceed 20 mg simvastatin daily with amiodarone, amlodipine and ranolazine; Patients should be closely monitored when taking fusidic acid with simvastatin. Temporary suspension of simvastatin treatment may be considered; Avoid grapefruit juice when taking simvastatin. **Undesirable effects:** The most commonly reported adverse drug reactions (ADRs) during Cholib therapy are increased blood creatinine, upper respiratory tract infection, increased platelet count, gastroenteritis and increased alanine aminotransferase.

For healthcare professional only. Full prescribing information available on request.

Abbott Laboratories Limited  
20/F, AIA Tower, 183 Electric Road, North Point Tel: (852) 2566 8711 Fax: (852) 2219 7397



New Drug Coming Soon  
Action Now

## TWO TREATMENTS ONE TABLET



Your combination for success  
in Mixed Dyslipidemia



HKG234619

For Medical Doctors, Clinics and Private Hospitals

# Introducing Cholib®

## The first fixed-dose combination of fenofibrate and simvastatin

### Indications<sup>1</sup>



- Adjuvant therapy to diet and exercise in high CV risk adult patients with mixed dyslipidemia to reduce TG and increase HDL-C levels when LDL-C levels are adequately controlled with the corresponding dose of simvastatin monotherapy

### Remarkable efficacy<sup>2</sup>



- Proven to reduce the residual CV risk associated with elevated TG and low HDL-C in high-risk patients with T2DM when simvastatin monotherapy does not adequately control the lipid profile

### Want to Know More?

Please fax to 2219 7712 or call your Abbott Representative

#### District

Central West / Sheung Wan / Mid-Level / Hong Kong Southern and Western District / Tai Wai / Shatin / Ma On Shan / Mongkok / Tai Kok Tsui / Sham Shui Po / Shek Kip Mei / Cheung Sha Wan / Lai Chi Kok / Mei Foo / Tsing Yi / Tuen Mun / Yuen Long / Tin Shui Wai / Tung Chung / Outlying Islands

Hunghom / To Kwa Wan / Ho Man Tin / Kowloon City / Lok Fu / Kwai Chung / Tsuen Wan / Chai Wan / Shau Kei Wan / Sai Wan Ho / Tai Koo Shing / Quarry Bay

Jordan / Yau Ma Tei / Wong Tai Sin / Tsz Wan Shan / Choi Hung / Kwloon Bay / Ngau Tau Kok / Kwan Tong / Lam Tin / Tsueng Kwan O / Sai Kung

Central East / Admiralty / Tai Po / Fanling / Sheung Shui

Tsim Sha Tsui / Causeway Bay / Wan Chai / Happy Valley / North Point

#### Representative

Francis Cheng

Francis Cheng

Tim Tang

Catherine Chan

Vivian Ng

#### Telephone no.

5236 8501

5236 8501

5236 8509

5236 8505

5236 8825

# Manage three lipid parameters, ONE TABLET

## Simple and convenient administration<sup>1</sup>



One tablet




Once a day



With or without food

Thanks to the advanced NanoCrystal® formulation of fenofibrate used in Cholib®



Date: \_\_\_\_\_

Zuellig Account Number: \_\_\_\_\_

Doctor's / Account Name: \_\_\_\_\_

Doctor's Email Address: \_\_\_\_\_

Mobile Number (for SMS contact): \_\_\_\_\_

Contact Person: \_\_\_\_\_ Contact Number: \_\_\_\_\_

Address: \_\_\_\_\_

\_\_\_\_\_